

ABSTRACT OF THE DISCLOSURE

5 The present invention relates to new methods of modifying
drug clearance and avoiding multi-drug resistance by modifying
SXR activity. SXR is a transcriptional activator of *MDR1*,
cytochrome P40-3A4 and cytochrome P40 2C8. SXR activation can
10 significantly increase the metabolic inactivation and efflux of
a wide range of chemotherapeutic agents, for example taxanes.
Reducing and/or preventing SXR activation therefore diminishes
drug resistance and drug clearance and forms the basis of
important therapeutic methods which increase the performance of
15 drugs, such as taxanes. Screening and drug identification
methods are described which can identify drugs which are not
susceptible to SXR related inactivation and increased efflux.
In addition, drugs which can reduce these effects for other
agents are provided.

1954-336.UT2